Study · Randomized controlled trial · n = 813 · 2018

11 results

Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.

Ahmann AJ, Capehorn M, Charpentier G, Dotta F, Henkel E, Lingvay I, Holst AG, Annett MP, Aroda VR

Diabetes care15 Dec 2017Cited by 481 (Europe PMC)

PMID29246950DOI10.2337/dc17-0417PepBankPUB-29246950

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on oral drugs, semaglutide 1.0 mg lowered HbA1c more than exenatide ER 2.0 mg at week 56.
In plain wordsIn adults with type 2 diabetes, semaglutide lowered HbA1c more than exenatide ER.
Peptide
Semaglutide
Outcome
DecreaseHbA1c change at week 56
Study
n = 813
Comparator
Exenatide ER 2.0 mg
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.0 mg once weekly · subcutaneous · 56 weeksAs given in this study (human).
Measurements
HbA1c change
−1.5%
semaglutide
HbA1c change
−0.9%
exenatide ER
Estimated treatment difference
−0.62%
vs exenatide ER
Source sentences
Summary
Mean HbA_1c (8.3% [67.7 mmol/mol] at baseline) was reduced by 1.5% (16.8 mmol/mol) with semaglutide and 0.9% (10.0 mmol/mol) with exenatide ER (estimated treatment difference vs. exenatide ER [ETD] -0.62% [95% CI -0.80, -0.44] [-6.78 mmol/mol (95% CI -8.70, -4.86)]; P < 0.0001 for n…
1 context sentence(design, population, supporting numbers)
Summary · context
In this phase 3a, open-label, parallel-group, randomized controlled trial, 813 subjects with type 2 diabetes taking oral antidiabetic drugs were randomized (1:1) to semaglutide 1.0 mg or exenatide ER 2.0 mg for 56 weeks.
Report a problemFND-2924695001
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes taking oral antidiabetic drugs, exenatide ER reduced HbA1c by 0.9% versus 1.5% with semaglutide 1.0 mg.
In plain wordsIn type 2 diabetes, exenatide reduced blood sugar less than semaglutide.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseHbA1c level versus semaglutide at week 56
Study
n = 813
Comparator
Semaglutide 1.0 mg
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
2.0 mg · subcutaneous · 56 weeksAs given in this study (human).
Measurements
HbA1c reduction from baseline
0.9%
exenatide ER
HbA1c reduction from baseline
10 mmol/mol
exenatide ER
HbA1c reduction from baseline
1.5%
semaglutide 1.0 mg
HbA1c reduction from baseline
16.8 mmol/mol
semaglutide 1.0 mg
Estimated treatment difference, semaglutide versus exenatide ER
−0.62%
semaglutide versus exenatide ER
Estimated treatment difference, semaglutide versus exenatide ER
−6.78 mmol/mol
semaglutide versus exenatide ER
Source sentences
Summary
Mean HbA_1c (8.3% [67.7 mmol/mol] at baseline) was reduced by 1.5% (16.8 mmol/mol) with semaglutide and 0.9% (10.0 mmol/mol) with exenatide ER (estimated treatment difference vs. exenatide ER [ETD] -0.62% [95% CI -0.80, -0.44] [-6.78 mmol/mol (95% CI -8.70, -4.86)]; P < 0.0001 for n…
2 context sentences(design, population, supporting numbers)
Summary · context
To compare the efficacy and safety of once-weekly semaglutide 1.0 mg s.c. with exenatide extended release (ER) 2.0 mg s.c. in subjects with type 2 diabetes.
Summary · context
In this phase 3a, open-label, parallel-group, randomized controlled trial, 813 subjects with type 2 diabetes taking oral antidiabetic drugs were randomized (1:1) to semaglutide 1.0 mg or exenatide ER 2.0 mg for 56 weeks.
Report a problemFND-2924695006
03HumanRandomized controlled trialEfficacy outcome
Semaglutide 1.0 mg reduced body weight more than exenatide ER 2.0 mg in adults with type 2 diabetes.
In plain wordsAdults on semaglutide lost more weight than adults on exenatide ER.
Peptide
Semaglutide
Outcome
DecreaseBody weight change at week 56
Study
n = 813
Comparator
Exenatide ER 2.0 mg
Outcome group
Body weight · Metabolic and weight
Studied dose
1.0 mg once weekly · subcutaneous · 56 weeksAs given in this study (human).
Measurements
Body weight change
−5.6 kg
semaglutide
Body weight change
−1.9 kg
exenatide ER
Estimated treatment difference
−3.78 kg
vs exenatide ER
Source sentences
Summary
Mean body weight (95.8 kg at baseline) was reduced by 5.6 kg with semaglutide and 1.9 kg with exenatide ER (ETD -3.78 kg [95% CI -4.58, -2.98]; P < 0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
In this phase 3a, open-label, parallel-group, randomized controlled trial, 813 subjects with type 2 diabetes taking oral antidiabetic drugs were randomized (1:1) to semaglutide 1.0 mg or exenatide ER 2.0 mg for 56 weeks.
Report a problemFND-2924695002
04HumanRandomized controlled trialEfficacy outcome
A larger proportion of adults treated with semaglutide than with exenatide ER reached HbA1c below 7.0%.
In plain wordsMore adults on semaglutide than on exenatide ER reached an HbA1c below 7.0%.
Peptide
Semaglutide
Outcome
IncreaseProportion reaching HbA1c below 7.0%
Study
n = 813
Comparator
Exenatide ER 2.0 mg
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.0 mg once weekly · subcutaneous · 56 weeksAs given in this study (human).
Measurements
Proportion with HbA1c <7.0%
67%
semaglutide
Proportion with HbA1c <7.0%
40%
exenatide ER
Source sentences
Summary
Significantly more subjects treated with semaglutide (67%) achieved HbA_1c <7.0% (<53 mmol/mol) versus those taking exenatide ER (40%).
1 context sentence(design, population, supporting numbers)
Summary · context
In this phase 3a, open-label, parallel-group, randomized controlled trial, 813 subjects with type 2 diabetes taking oral antidiabetic drugs were randomized (1:1) to semaglutide 1.0 mg or exenatide ER 2.0 mg for 56 weeks.
Report a problemFND-2924695003
05HumanRandomized controlled trialSafety outcome
Gastrointestinal adverse events were more common with semaglutide than with exenatide ER.
In plain wordsStomach and gut side effects were more common with semaglutide than with exenatide ER.
Peptide
Semaglutide
Outcome
IncreaseGastrointestinal adverse events
Study
n = 813
Comparator
Exenatide ER 2.0 mg
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
1.0 mg once weekly · subcutaneous · 56 weeksAs given in this study (human).
Measurements
Gastrointestinal adverse events
41.8%
semaglutide
Gastrointestinal adverse events
33.3%
exenatide ER
Source sentences
Summary
gastrointestinal adverse events were more common in semaglutide-treated subjects (41.8%) than in exenatide ER-treated subjects (33.3%)
1 context sentence(design, population, supporting numbers)
Summary · context
In this phase 3a, open-label, parallel-group, randomized controlled trial, 813 subjects with type 2 diabetes taking oral antidiabetic drugs were randomized (1:1) to semaglutide 1.0 mg or exenatide ER 2.0 mg for 56 weeks.
Report a problemFND-2924695004
06HumanRandomized controlled trialSafety outcome
Injection-site reactions were less frequent with semaglutide than with exenatide ER.
In plain wordsInjection-site reactions were less frequent with semaglutide than with exenatide ER.
Peptide
Semaglutide
Outcome
DecreaseInjection-site reactions
Study
n = 813
Comparator
Exenatide ER 2.0 mg
Outcome group
Adverse events · Whole body
Studied dose
1.0 mg once weekly · subcutaneous · 56 weeksAs given in this study (human).
Measurements
Injection-site reactions
1.2%
semaglutide
Injection-site reactions
22%
exenatide ER
Source sentences
Summary
injection-site reactions were more frequent with exenatide ER (22.0%) than with semaglutide (1.2%)
1 context sentence(design, population, supporting numbers)
Summary · context
In this phase 3a, open-label, parallel-group, randomized controlled trial, 813 subjects with type 2 diabetes taking oral antidiabetic drugs were randomized (1:1) to semaglutide 1.0 mg or exenatide ER 2.0 mg for 56 weeks.
Report a problemFND-2924695005
07HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes taking oral antidiabetic drugs, exenatide ER reduced body weight by 1.9 kg versus 5.6 kg with semaglutide 1.0 mg.
In plain wordsIn type 2 diabetes, exenatide reduced weight less than semaglutide.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseBody weight versus semaglutide
Study
n = 813
Comparator
Semaglutide 1.0 mg
Outcome group
Body weight · Metabolic and weight
Studied dose
2.0 mg · subcutaneous · 56 weeksAs given in this study (human).
Measurements
Body weight reduction
1.9 kg
exenatide ER
Body weight reduction
5.6 kg
semaglutide 1.0 mg
Estimated treatment difference, semaglutide versus exenatide ER
−3.78 kg
semaglutide versus exenatide ER
Source sentences
Summary
Mean body weight (95.8 kg at baseline) was reduced by 5.6 kg with semaglutide and 1.9 kg with exenatide ER (ETD -3.78 kg [95% CI -4.58, -2.98]; P < 0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
To compare the efficacy and safety of once-weekly semaglutide 1.0 mg s.c. with exenatide extended release (ER) 2.0 mg s.c. in subjects with type 2 diabetes.
Summary · context
In this phase 3a, open-label, parallel-group, randomized controlled trial, 813 subjects with type 2 diabetes taking oral antidiabetic drugs were randomized (1:1) to semaglutide 1.0 mg or exenatide ER 2.0 mg for 56 weeks.
Report a problemFND-2924695007
08HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, 40% receiving exenatide achieved HbA1c below 7.0% versus 67% receiving semaglutide.
In plain wordsIn type 2 diabetes, fewer participants reached the blood sugar target with exenatide than semaglutide.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseHbA1c below target
Study
n = 813
Comparator
Semaglutide 1.0 mg
Outcome group
Glycemic control · Metabolic and weight
Studied dose
2.0 mg · subcutaneous · 56 weeksAs given in this study (human).
Measurements
Subjects achieving HbA1c <7.0%
40%
exenatide ER
Subjects achieving HbA1c <7.0%
67%
semaglutide 1.0 mg
Source sentences
Summary
Significantly more subjects treated with semaglutide (67%) achieved HbA_1c <7.0% (<53 mmol/mol) versus those taking exenatide ER (40%).
2 context sentences(design, population, supporting numbers)
Summary · context
To compare the efficacy and safety of once-weekly semaglutide 1.0 mg s.c. with exenatide extended release (ER) 2.0 mg s.c. in subjects with type 2 diabetes.
Summary · context
In this phase 3a, open-label, parallel-group, randomized controlled trial, 813 subjects with type 2 diabetes taking oral antidiabetic drugs were randomized (1:1) to semaglutide 1.0 mg or exenatide ER 2.0 mg for 56 weeks.
Report a problemFND-2924695008
09HumanRandomized controlled trialSafety outcome
In type 2 diabetes, exenatide and semaglutide had similar safety profiles.
In plain wordsIn type 2 diabetes, exenatide and semaglutide had similar safety profiles.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeOverall safety profile
Study
n = 813
Comparator
Semaglutide 1.0 mg
Outcome group
Adverse events · Whole body
Studied dose
2.0 mg · subcutaneous · 56 weeksAs given in this study (human).
Source sentences
Summary
Both treatments had similar safety profiles
2 context sentences(design, population, supporting numbers)
Summary · context
To compare the efficacy and safety of once-weekly semaglutide 1.0 mg s.c. with exenatide extended release (ER) 2.0 mg s.c. in subjects with type 2 diabetes.
Summary · context
In this phase 3a, open-label, parallel-group, randomized controlled trial, 813 subjects with type 2 diabetes taking oral antidiabetic drugs were randomized (1:1) to semaglutide 1.0 mg or exenatide ER 2.0 mg for 56 weeks.
Report a problemFND-2924695009
10HumanRandomized controlled trialSafety outcome
In type 2 diabetes, gastrointestinal adverse events occurred in 33.3% with exenatide versus 41.8% with semaglutide.
In plain wordsIn type 2 diabetes, gut adverse events were less frequent with exenatide than semaglutide.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseGastrointestinal adverse events
Study
n = 813
Comparator
Semaglutide 1.0 mg
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
2.0 mg · subcutaneous · 56 weeksAs given in this study (human).
Measurements
Gastrointestinal adverse event incidence
33.3%
exenatide ER
Gastrointestinal adverse event incidence
41.8%
semaglutide 1.0 mg
Source sentences
Summary
gastrointestinal adverse events were more common in semaglutide-treated subjects (41.8%) than in exenatide ER-treated subjects (33.3%)
2 context sentences(design, population, supporting numbers)
Summary · context
To compare the efficacy and safety of once-weekly semaglutide 1.0 mg s.c. with exenatide extended release (ER) 2.0 mg s.c. in subjects with type 2 diabetes.
Summary · context
In this phase 3a, open-label, parallel-group, randomized controlled trial, 813 subjects with type 2 diabetes taking oral antidiabetic drugs were randomized (1:1) to semaglutide 1.0 mg or exenatide ER 2.0 mg for 56 weeks.
Report a problemFND-2924695010
11HumanRandomized controlled trialSafety outcome
In type 2 diabetes, injection-site reactions occurred in 22.0% with exenatide versus 1.2% with semaglutide.
In plain wordsIn type 2 diabetes, injection-site reactions were more frequent with exenatide than semaglutide.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseInjection-site reactions
Study
n = 813
Comparator
Semaglutide 1.0 mg
Outcome group
Adverse events · Skin and wound
Studied dose
2.0 mg · subcutaneous · 56 weeksAs given in this study (human).
Measurements
Injection-site reaction incidence
22%
exenatide ER
Injection-site reaction incidence
1.2%
semaglutide 1.0 mg
Source sentences
Summary
injection-site reactions were more frequent with exenatide ER (22.0%) than with semaglutide (1.2%).
2 context sentences(design, population, supporting numbers)
Summary · context
To compare the efficacy and safety of once-weekly semaglutide 1.0 mg s.c. with exenatide extended release (ER) 2.0 mg s.c. in subjects with type 2 diabetes.
Summary · context
In this phase 3a, open-label, parallel-group, randomized controlled trial, 813 subjects with type 2 diabetes taking oral antidiabetic drugs were randomized (1:1) to semaglutide 1.0 mg or exenatide ER 2.0 mg for 56 weeks.
Report a problemFND-2924695011

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials4

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

4 trials · 2 ongoing · 2 completed · 2 with posted results · source ClinicalTrials.gov (opens in a new tab)

RecruitingPhase 2/3NCT07284511

A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar

McGill University Health Centre/Research Institute of the McGill University Health Centren = 10519 May 2026 to est. Jan 2029

Type 1 Diabetes · Type 1 Diabetes Mellitus · T1D · T1DM · T1DM - Type 1 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 27 May 2026

RecruitingPhase 3NCT06894784

A Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes

McGill University Health Centre/Research Institute of the McGill University Health Centren = 36est. Apr 2025 to est. Jan 2027

Diabetes Type 1

Trial page ClinicalTrials.govUpdated 30 Mar 2025

CompletedPhase 3Results postedNCT02648204

Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.

Novo Nordisk A/Sn = 1,2016 Jan 2016 to 19 May 2017

Diabetes · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 15 Oct 2019

CompletedPhase 3Results postedNCT01885208

Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes

Novo Nordisk A/Sn = 8132 Dec 2013 to 13 Jul 2015

Diabetes · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 13 Jun 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 4 to 9Current
28 Oct 2026, 02:03 UTC
The same notice was added 6 times, first on 22 Oct 2026, 02:26 UTC. The status did not change between them.
Study results updated
Version 3
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 2
11 Oct 2026, 00:50 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.